Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model

Purpose Immunosuppressive and anti-inflammatory agents have recently become increasingly popular in the treatment of encapsulating peritoneal sclerosis (EPS). The aim of our study was to investigate the effects of sirolimus on EPS in a rat model. Methods We separated 32 non-uremic rats into four groups: 1 control group, 2 ml isotonic saline injected IP daily for 3 weeks; 2 chlorhexidine gluconate (CG) group, 2 ml 0,1 % CG and 15 % ethanol dissolved in saline injected IP daily for 3 weeks; 3 resting group, CG (weeks 0-3) plus peritoneal rest (weeks 3-6); 4 sirolimus group, CG (weeks 0-3), plus 0.2 ml (1 mg/ml) sirolimus (weeks 3-6). Pathological samples were examined by using hematoxylin eosin (HE) and Masson's trichrome stains. Peritoneal thickness, fibrosis, vascular changes, and inflammation were evaluated by light microscopy. Finally, tissue metalloproteinase (MMP)-2 levels were measured by enzyme-linked immunoassay. Results In the CG group, there was a significant increase in peritoneal thickness, inflammatory activity, and fibrosis score compared to the control group (p<0.05). We also observed a lower fibrosis score and less peritoneal thickening in the sirolimus group compared to the resting and CG groups (p<0.05). There was no difference in histopathologic findings, except for the inflammatory activity in the sirolimus group, compared to the control group. Although the CG group had higher tissue MMP-2 levels than the control group, the tissue MMP-2 levels were not significantly different from the other groups. Conclusions Sirolimus has a beneficial effect on peritoneal fibrosis induced by CG. This suggests that sirolimus may have therapeutic value in the management of EPS. © Springer Science+Business Media, B.V. 2011.

Yazar Ceri M.
Unverdi S.
Dogan M.
Unverdi H.
Karaca G.
Kocak G.
Kurultak I.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/5379
Tek Biçim Adres 10.1007/s11255-012-0167-3
Konu Başlıkları Chlorhexidine gluconate
Fibrosis
Peritoneal dialysis
Sirolimus
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı International Urology and Nephrology
Dergi Cilt Bilgisi 44
Dergi Sayısı 3
Sayfalar 977 - 982
Yayın Yılı 2012
Eser Adı
[dc.title]
Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model
Yazar
[dc.contributor.author]
Ceri M.
Yazar
[dc.contributor.author]
Unverdi S.
Yazar
[dc.contributor.author]
Dogan M.
Yazar
[dc.contributor.author]
Unverdi H.
Yazar
[dc.contributor.author]
Karaca G.
Yazar
[dc.contributor.author]
Kocak G.
Yazar
[dc.contributor.author]
Kurultak I.
Yayın Yılı
[dc.date.issued]
2012
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Purpose Immunosuppressive and anti-inflammatory agents have recently become increasingly popular in the treatment of encapsulating peritoneal sclerosis (EPS). The aim of our study was to investigate the effects of sirolimus on EPS in a rat model. Methods We separated 32 non-uremic rats into four groups: 1 control group, 2 ml isotonic saline injected IP daily for 3 weeks; 2 chlorhexidine gluconate (CG) group, 2 ml 0,1 % CG and 15 % ethanol dissolved in saline injected IP daily for 3 weeks; 3 resting group, CG (weeks 0-3) plus peritoneal rest (weeks 3-6); 4 sirolimus group, CG (weeks 0-3), plus 0.2 ml (1 mg/ml) sirolimus (weeks 3-6). Pathological samples were examined by using hematoxylin eosin (HE) and Masson's trichrome stains. Peritoneal thickness, fibrosis, vascular changes, and inflammation were evaluated by light microscopy. Finally, tissue metalloproteinase (MMP)-2 levels were measured by enzyme-linked immunoassay. Results In the CG group, there was a significant increase in peritoneal thickness, inflammatory activity, and fibrosis score compared to the control group (p<0.05). We also observed a lower fibrosis score and less peritoneal thickening in the sirolimus group compared to the resting and CG groups (p<0.05). There was no difference in histopathologic findings, except for the inflammatory activity in the sirolimus group, compared to the control group. Although the CG group had higher tissue MMP-2 levels than the control group, the tissue MMP-2 levels were not significantly different from the other groups. Conclusions Sirolimus has a beneficial effect on peritoneal fibrosis induced by CG. This suggests that sirolimus may have therapeutic value in the management of EPS. © Springer Science+Business Media, B.V. 2011.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Chlorhexidine gluconate
Konu Başlıkları
[dc.subject]
Fibrosis
Konu Başlıkları
[dc.subject]
Peritoneal dialysis
Konu Başlıkları
[dc.subject]
Sirolimus
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0301-1623
İlk Sayfa Sayısı
[dc.identifier.startpage]
977
Son Sayfa Sayısı
[dc.identifier.endpage]
982
Dergi Adı
[dc.relation.journal]
International Urology and Nephrology
Dergi Sayısı
[dc.identifier.issue]
3
Dergi Cilt Bilgisi
[dc.identifier.volume]
44
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/s11255-012-0167-3
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/5379
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
19
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
07 Şubat 2024 10:39
Google Kontrol
Tıklayınız
sirolimus peritoneal (weeks fibrosis control levels tissue groups compared thickness inflammatory activity injected resting saline Results management observed Springer Science+Business measured increase enzyme-linked significant immunoassay thickening difference significantly different Conclusions Sirolimus beneficial higher effect induced
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms